NASDAQ · NIVFW

NewGenIvf Group Limited

$0.03 -$0.01 (-26.86%) 1D Pre-market

Key Metrics

Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow −$11.06M
Beta · 1Y 0.27
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 1
    From its May 28 high, the share price fell 59%.

    Peak close $0.04 on May 28; trough close $0.02 on Jun 1. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -59%
  • May 22
    The stock moved +90.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 22
  • Apr 30
    The stock moved +78.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.01 – $0.09
Avg volume · 20D33.4K
Net cash
Book value / share
ExchangeNASDAQ
About NewGenIvf Group Limited
IPO dateApr 4, 2024
Employees87

NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio3.12
Quick ratio2.98
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.02M

Cash Flow · TTM

Operating CF −$10.93M
Capex −$135.03K
Free cash flow −$11.06M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings